Home Topics Drug Discovery $3.25B Tysabri Deal a Win-Win for Biogen Idec, Elan Biogen Idec’s $3.25 billion-plus-royalties purchase of all rights to Tysabri (natalizumab), the multiple sclerosis drug it co-developed with Elan, boosts Biogen Idec’s presence in MS drugs while leaving the Irish-owned biotech in the enviable position of having control of its future, and some spending cash to boot, afte
![$3.25B Tysabri Deal a Win-Win for Biogen Idec, Elan](https://cdn-ak-scissors.b.st-hatena.com/image/square/4f0066c696a2d775a4f9787615fa7ba7fabc2cfd/height=288;version=1;width=512/https%3A%2F%2Fwww.genengnews.com%2Fwp-content%2Fuploads%2F2018%2F08%2FJan29_2013_Waksal_thumbnail1381792062.jpg)